Your browser doesn't support javascript.
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Berenguer, Juan; Díez, Cristina; Martín-Vicente, María; Micán, Rafael; Pérez-Elías, María J; García-Fraile, Lucio J; Vidal, Francisco; Suárez-García, Inés; Podzamczer, Daniel; Del Romero, Jorge; Pulido, Federico; Iribarren, José A; Gutiérrez, Félix; Poveda, Eva; Galera, Carlos; Izquierdo, Rebeca; Asensi, Víctor; Portilla, Joaquín; López, Juan C; Arribas, José R; Moreno, Santiago; González-García, Juan; Resino, Salvador; Jarrín, Inmaculada.
  • Berenguer J; Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain. Electronic address: jbb4@me.com.
  • Díez C; Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain.
  • Martín-Vicente M; Centro Nacional de Microbiología (ISCIII), Majadahonda, Spain.
  • Micán R; Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
  • Pérez-Elías MJ; Hospital Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain.
  • García-Fraile LJ; Hospital Universitario de La Princesa, Madrid, Spain.
  • Vidal F; Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain.
  • Suárez-García I; Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, San Sebastián de los Reyes, Universidad Europea de Madrid, Spain.
  • Podzamczer D; Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Del Romero J; Centro Sandoval, Madrid, Spain.
  • Pulido F; Hospital Universitario 12 Octubre, imas12, Universidad Complutense de Madrid, Madrid, Spain.
  • Iribarren JA; Hospital Universitario Donostia, II BioDonostia, San Sebastián, Spain.
  • Gutiérrez F; Hospital Universitario de Elche, Universidad Miguel Hernández, Elche, Spain.
  • Poveda E; Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Spain.
  • Galera C; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Izquierdo R; Centro Nacional de Epidemiología (ISCIII), Madrid, Spain.
  • Asensi V; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Portilla J; Hospital General Universitario de Alicante, Alicante, Spain.
  • López JC; Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain.
  • Arribas JR; Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
  • Moreno S; Hospital Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain.
  • González-García J; Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
  • Resino S; Centro Nacional de Microbiología (ISCIII), Majadahonda, Spain.
  • Jarrín I; Centro Nacional de Epidemiología (ISCIII), Madrid, Spain.
Clin Microbiol Infect ; 27(11): 1678-1684, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1284006
ABSTRACT

OBJECTIVES:

We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).

METHODS:

This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.

RESULTS:

Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm3, 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).

CONCLUSIONS:

Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Variants Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Variants Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article